Antibody biosimilars: Fears or opportunities?
نویسندگان
چکیده
The industrial workshop “Antibody biosimilars” was opened by Hervé Watier (CNRS UMR 7292, Université FrançoisRabelais de Tours, France), coordinator of the MAbImprove Laboratory of Excellence. He delivered his welcome address, starting with a quick recall of the LabEx MAbImprove story. This LabEx was created in 2011 and funded by “Investment for the Future” program (French “Big Loan”). He then introduced this industrial workshop as a yearly event dedicated to real life in the biopharmaceutical industry, invited to present and to discuss current issues to academics. He invited all attendees to debate in depth on this very timely “Antibody Biosimilars” topic, and to open discussions between the industry developing biosimilars and those who develop only novel products. Finally, he reminded participants that biosimilarity is not only a matter of structure, but also of function and pharmacology, which are the main topics of the LabEx MAbImprove. Prof. Loïc Vaillant (President of the Université François-Rabelais de Tours, France) welcomed all attendees, in particular those from outside France. After a brief presentation of the University, he emphasized the importance of interdisciplinarity and international research networks. Moreover, he underlined the necessity of tight collaboration between the educational institution and the industrial field. He pointed out the importance of the LabEx MAbImprove in the French biotechnological landscape. Indeed, France is an outsider in the field and the government is willing to change this situation. MAbImprove is not only a research tool (with 200 researchers working on monoclonal therapeutic antibodies in Tours and Montpellier), but also a support for biopharmaceutical *Correspondence to: Hervé Watier; Email: [email protected] Submitted: 04/03/14; Accepted: 04/03/14; Published Online: 04/08/2014 http://dx.doi.org/10.4161/mabs.28831 Antibody biosimilars: Fears or opportunities? First LabEx MAbImprove industrial workshop, May 28, 2013 Tours, France
منابع مشابه
Biosimilar Products Scientific Principles , Challenges , and Opportunities
T he Chemistry, Manufacturing, and Controls (CMC) Strategy Forum held on 22 January 2012 in San Francisco, CA, focused on selected scientific and regulatory aspects in the development of biosimilar products. Such products are becoming an increasingly important area of interest for both the biopharmaceutical industry and regulatory agencies. Biosimilars are highly complex, and scientists have be...
متن کاملPerspectives Biosimilars: the science of extrapolation
Since the establishment of a specific approval pathway for similar biological medicinal products, so-called “biosimilars,” several biosimilars have been licensed and become available in the European Union (EU). However, despite a stringent approval process, acceptance of biosimilars in the medical community continues to be low. This appears to be especially true for therapeutic indications, for...
متن کاملRituximab and biosimilars - equivalence and reciprocity.
Cancer is a debilitating disease affecting millions of people daily. Over the years, cancer treatment has advanced in leaps and bounds. Antibodies are important breakthrough therapeutic agents for cancer. These agents, proteins produced by B lymphocytes of the immune system in response to antigens, bind to receptors on cell surfaces so that the antigen-antibody complexes can be recognized and d...
متن کاملA Comparison of US and EU Biosimilars Regimes
Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different from the generic small molecule pharmaceutical industry. The sharp demarcation between branded and generic small molecule pharmaceutical companies may not exist in the biologics context. The emerging biosimilars industry may present opportunities for both p...
متن کاملBiosimilars: A Multidisciplinary Perspective.
A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient access compared with biologics are a significant appeal of biosimilars. Regulatory guidelines for biosimilar development and approval are rigorous and undergoing constant refinement. The process of licensing approval for all biosimilars requires demons...
متن کامل